PORTFOLIO NEWS Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion March 26, 2024 Read More » A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors March 25, 2024 Read More » Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) March 25, 2024 Read More » Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting March 20, 2024 Read More » Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 18, 2024 Read More » Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine March 18, 2024 Read More » ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates March 11, 2024 Read More » NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results March 11, 2024 Read More » Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial March 11, 2024 Read More » RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 7, 2024 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion March 26, 2024 Read More »
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors March 25, 2024 Read More »
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) March 25, 2024 Read More »
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting March 20, 2024 Read More »
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 18, 2024 Read More »
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine March 18, 2024 Read More »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates March 11, 2024 Read More »
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results March 11, 2024 Read More »
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial March 11, 2024 Read More »
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 7, 2024 Read More »
